Generic CellCept ( Mycofenolate mofetil )

Order cheap Generic CellCept (Mycofenolate mofetil) without dr prescription in the United States

In our USA pharmacy, you can buy CellCept without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
CellCept (mycophenolate mofetil) is a potent immunosuppressive agent used to prevent organ rejection in patients who have received kidney, heart, or liver transplants. It works by inhibiting an enzyme critical for the synthesis of purines, which are building blocks for DNA and RNA; this action selectively suppresses the proliferation of T and B lymphocytes, the cells responsible for attacking a transplanted organ.
Usual adult dose: For renal transplantation, 1 g orally twice daily (two 500 mg tablets twice daily). For cardiac or hepatic transplantation, 1.5 g orally twice daily (three 500 mg tablets twice daily). The first dose should be given as soon as possible after transplantation.
Dosage form: Film‑coated oral tablets (500 mg); also available as 250 mg capsules, oral suspension (200 mg/mL), and injection for intravenous use.
Onset of action: Peak immunosuppressive effect occurs within 6‑12 weeks of continuous therapy, but the drug begins to act upon the first dose; steady‑state levels are reached within days.
Duration of action: Oral doses are given every 12 hours to maintain therapeutic levels; the active metabolite mycophenolic acid has a half‑life of about 16‑18 hours.
Alcohol consumption should be limited; excessive intake may increase the risk of gastrointestinal irritation and liver enzyme abnormalities, especially in transplant patients taking other hepatically metabolized drugs.
Most common side effects: diarrhea, leukopenia, nausea, vomiting, and increased risk of infections.
Would you like to try CellCept without a prescription?

General Information about CellCept

• INN (International Nonproprietary Name): Mycophenolate mofetil
• Brand names available in the USA: CellCept® (Genentech USA, Inc., a member of the Roche Group). Generic mycophenolate mofetil is available from multiple FDA‑approved manufacturers, including Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., Sandoz Inc., Accord Healthcare, Inc., and others.
• ATC code: L04AA06
• Dosage forms and strengths: Film‑coated tablets: 500 mg; capsules: 250 mg; powder for oral suspension: 200 mg/mL after reconstitution; lyophilized powder for intravenous infusion: 500 mg per vial.
• Manufacturers in USA: Genentech USA, Inc. (brand CellCept®); generic manufacturers include Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., Sandoz Inc., Accord Healthcare, Inc., and other authorized companies.
• Registration status in USA: Approved by the U.S. Food and Drug Administration (FDA) on May 3, 1995 (NDA 050722).
• OTC / Rx classification: Prescription only (Rx).

Mechanism of Action and Pharmacology

Mycophenolate mofetil is a prodrug that is rapidly hydrolyzed after oral or intravenous administration to its active metabolite, mycophenolic acid (MPA). MPA is a potent, selective, non‑competitive, and reversible inhibitor of inosine‑5‑monophosphate dehydrogenase (IMPDH), an enzyme essential for the de novo synthesis of guanosine nucleotides. Unlike most other cell types, lymphocytes are critically dependent on the de novo pathway for purine biosynthesis because they lack the salvage pathway. By blocking IMPDH, MPA depletes guanosine nucleotide pools preferentially in T and B lymphocytes, thereby inhibiting their proliferation and suppressing both cell‑mediated and humoral immune responses. MPA also inhibits the glycosylation and expression of adhesion molecules and may suppress the recruitment of lymphocytes and monocytes to sites of inflammation and graft rejection. After oral administration, mycophenolate mofetil is absorbed in the stomach and small intestine and undergoes extensive enterohepatic recirculation of MPA glucuronide metabolites, which are converted back to MPA. Peak MPA concentrations are reached 1‑1.5 hours after dosing. The terminal elimination half‑life of MPA is 16‑18 hours. Excretion is primarily renal as MPA glucuronide.

Indications

• Prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants. CellCept must be used concomitantly with cyclosporine, tacrolimus, or sirolimus and corticosteroids.
• Off‑label uses: treatment of autoimmune diseases such as lupus nephritis, systemic lupus erythematosus, vasculitis, myasthenia gravis, and inflammatory bowel disease.

Important Warnings and Precautions

CELLCEPT CARRIES A BOXED WARNING FOR EMBRYO‑FETAL TOXICITY, including an increased risk of first‑trimester pregnancy loss and congenital malformations, particularly external ear and other facial abnormalities, cleft palate, and distal limb, heart, esophagus, and kidney malformations. Pregnancy must be excluded before initiation, and women of childbearing potential must use two reliable forms of contraception simultaneously for 4 weeks prior to, during, and for 6 weeks after stopping therapy. Mycophenolate is also associated with an increased risk of lymphoma and other malignancies, particularly skin cancers. Patients should limit sun exposure and use adequate sun protection. Serious infections, including opportunistic infections such as cytomegalovirus, BK virus‑associated nephropathy, and progressive multifocal leukoencephalopathy (PML), may occur. Neutropenia and pure red cell aplasia have been reported; complete blood counts should be monitored regularly, and treatment interruption or dose reduction may be necessary. Gastrointestinal bleeding and perforation have been observed, especially in patients with pre‑existing gastrointestinal disease. Vaccination with live vaccines should be avoided during treatment.

At‑risk groups

• Elderly: No specific dose adjustment is recommended based solely on age; however, the risk of adverse events may be higher due to age‑related decreases in renal and hepatic function.
• Pregnancy: ABSOLUTELY CONTRAINDICATED unless the benefit clearly outweighs the risk. Category D. Mycophenolate mofetil causes embryo‑fetal toxicity. Women of childbearing potential must use two effective forms of contraception and have a negative pregnancy test before starting therapy. Males should use condoms during treatment and for 90 days after stopping because mycophenolate is present in semen.
• Breastfeeding: Contraindicated. Mycophenolate mofetil is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding must be discontinued during therapy.
• Renal impairment: No dose adjustment is required for renal transplant patients. For other transplant patients with severe chronic renal impairment (glomerular filtration rate
• Hepatic impairment: No dose adjustment is required for renal transplant patients with severe hepatic parenchymal disease. Caution is advised in liver transplant patients; the recommended dose is 1 g twice daily intravenously or orally, and higher doses may be associated with increased gastrointestinal bleeding.
• Pediatric: CellCept is approved for prophylaxis of organ rejection in pediatric renal transplant patients 3 months and older. Dosing is based on body surface area (600 mg/m² orally twice daily, up to a maximum of 2 g per day). Safety in pediatric cardiac or hepatic transplant patients has not been established.
• Immunocompromised state: Patients must be monitored closely for signs of infection and malignancy throughout therapy.

Driving and alcohol

CellCept is not known to impair the ability to drive or operate machinery. However, some patients may experience dizziness, confusion, or somnolence as adverse effects, which could indirectly affect driving. Alcohol consumption should be limited; heavy alcohol intake may exacerbate gastrointestinal side effects and increase the risk of liver toxicity, particularly in transplant patients receiving hepatically metabolized immunosuppressants.

Dosage Instructions

• Renal transplantation – adults: 1 g orally twice daily (total daily dose 2 g), initiated as soon as possible after transplantation.
• Cardiac or hepatic transplantation – adults: 1.5 g orally twice daily (total daily dose 3 g).
• Pediatric renal transplantation (3 months to 18 years): 600 mg/m² orally twice daily, up to a maximum of 2 g per day. The oral suspension is the preferred formulation for children.
• Intravenous administration: 1 g (renal) or 1.5 g (cardiac/hepatic) infused over at least 2 hours, twice daily, for up to 14 days, then convert to oral therapy as soon as tolerated.
• Administration: Tablets and capsules should be swallowed whole with a full glass of water. Do not crush, chew, or open capsules. If oral suspension is used, it should be prepared by a pharmacist and administered using the provided oral dosing syringe. Shake the reconstituted suspension well before each use.
• Missed dose: If a dose is missed, take it as soon as remembered. If it is almost time for the next dose (within 6 hours), skip the missed dose and resume the regular schedule. Do not double the dose.
• Therapeutic drug monitoring: Monitoring of mycophenolic acid trough levels may be considered, particularly in patients at higher risk of rejection or toxicity. Target trough concentrations are typically 1.3‑3.5 µg/mL.
• Dose adjustments for neutropenia (ANC : Interruption or dose reduction is recommended. Discontinue if severe, persistent neutropenia develops.

Side Effects and Contraindications

Most common adverse reactions (incidence ≥20%): Diarrhea (up to 50%), leukopenia (including neutropenia), nausea, vomiting, and increased susceptibility to infections, particularly cytomegalovirus, herpes simplex, herpes zoster, and candidiasis. Diarrhea and leukopenia are dose‑dependent and often necessitate dose adjustment.
Other common adverse reactions: Headache, tremor, hypertension, hypotension, peripheral edema, dyspnea, cough, rash, anemia, thrombocytopenia, hypercholesterolemia, hypomagnesemia, hyperglycemia, and renal function impairment.
Serious adverse reactions: Lymphoma and other malignancies (especially skin), progressive multifocal leukoencephalopathy (PML), BK virus‑associated nephropathy, pure red cell aplasia, severe neutropenia, gastrointestinal perforation, and increased risk of congenital malformations when taken during pregnancy. Sepsis and other serious bacterial, viral, and fungal infections can be fatal.
Absolute contraindications: Known hypersensitivity to mycophenolate mofetil, mycophenolic acid, or any excipients; pregnancy (unless no alternative and the benefit justifies the risk); breastfeeding; and vaccination with live vaccines during therapy.

Drug Interactions

• Azathioprine: Avoid concomitant use because both drugs inhibit purine metabolism and may cause additive myelosuppression.
• Antacids containing magnesium or aluminum hydroxide: Significantly decrease the absorption of mycophenolate mofetil when administered simultaneously. Separate administration by at least 2 hours.
• Cholestyramine and bile acid sequestrants: Interrupt enterohepatic recirculation and reduce mycophenolic acid exposure by approximately 40%. Avoid concomitant use; if necessary, separate by several hours and monitor mycophenolic acid levels.
• Cyclosporine: Cyclosporine reduces the enterohepatic recirculation of mycophenolic acid, lowering exposure. When cyclosporine is discontinued or substituted, mycophenolic acid levels may rise, requiring dose adjustment.
• Sevelamer: Significantly reduces mycophenolic acid peak concentration and overall exposure. Administer mycophenolate at least 1 hour before or 3 hours after sevelamer.
• Proton pump inhibitors (PPIs) and H2‑receptor antagonists: May reduce mycophenolate absorption; no specific dose adjustment is recommended, but therapeutic drug monitoring may be considered.
• Rifampin: Reduces mycophenolic acid exposure; dose increase may be needed if rifampin is co‑administered.
• Oral contraceptives: Mycophenolate may reduce the efficacy of hormonal contraceptives. Women of childbearing potential must use two reliable forms of contraception, including a barrier method, regardless of oral contraceptive use.
• Live vaccines: Contraindicated during therapy due to the risk of vaccine‑induced infection.
• Acyclovir, ganciclovir, valganciclovir: These drugs compete with mycophenolic acid glucuronide for renal tubular secretion and may increase concentrations of both agents; use with caution, especially in renal impairment.

Practical Advice

• Take CellCept exactly as prescribed, twice daily at the same times every day (e.g., 8 AM and 8 PM). Swallow tablets or capsules whole with a full glass of water. Do not crush, chew, or open capsules.
• If you are taking the oral suspension, shake the bottle well before measuring each dose. Use only the oral dosing syringe provided by the pharmacist. Rinse the syringe with water after use.
• If a dose is missed, take it as soon as you remember. If it is less than 6 hours until your next scheduled dose, skip the missed dose. Do not double doses to catch up.
• Do not stop taking CellCept without consulting your transplant team. Discontinuation increases the risk of acute organ rejection, which may lead to graft loss.
• Women of childbearing potential must have a negative pregnancy test immediately before starting therapy and must use two reliable forms of contraception simultaneously for 4 weeks before treatment, throughout therapy, and for 6 weeks after stopping. Male patients should use condoms during treatment and for 90 days after stopping. Mycophenolate is present in semen and may pose a fetal risk.
• Avoid prolonged sun exposure and tanning beds. Use a broad‑spectrum sunscreen (SPF 30 or higher) and wear protective clothing to reduce the risk of skin cancer.
• Report immediately any signs of infection: fever, chills, sore throat, mouth ulcers, unusual bruising or bleeding, or any other symptoms suggesting an infection. Infection may require immediate medical attention.
• Do not receive live vaccines (e.g., MMR, varicella, shingles, intranasal influenza, rotavirus) while taking CellCept. Inactivated vaccines may be administered but may be less effective.
• Attend all scheduled blood tests, including complete blood count with differential, renal function, and liver function tests. Regular monitoring is essential to detect neutropenia, anemia, or other toxicities early.
• Do not donate blood during therapy and for at least 6 weeks after stopping. Do not donate sperm during therapy and for 90 days after stopping.
• Store CellCept tablets, capsules, and oral suspension powder at room temperature (15‑30°C / 59‑86°F). Protect from light and moisture. Reconstituted oral suspension should be stored in the refrigerator (2‑8°C / 36‑46°F) and discarded after 60 days. Keep out of reach of children.

Alternative Medications

• Myfortic® (mycophenolic acid delayed‑release tablets): An enteric‑coated formulation of the active metabolite designed to reduce gastrointestinal side effects. Indicated for prophylaxis of organ rejection in renal transplant recipients. Tablets: 180 mg and 360 mg.
• Azathioprine (Imuran®): An older purine synthesis inhibitor used for maintenance immunosuppression in transplantation and autoimmune diseases. Associated with a higher risk of myelosuppression and less effective than mycophenolate for preventing acute rejection.
• Tacrolimus (Prograf®, Astagraf XL®, Envarsus XR®): A calcineurin inhibitor that is the cornerstone of most modern immunosuppressive regimens. Used in combination with mycophenolate and corticosteroids.
• Cyclosporine (Neoral®, Gengraf®): Another calcineurin inhibitor; often used in place of tacrolimus for patients who cannot tolerate tacrolimus or in specific transplant protocols.
• Sirolimus (Rapamune®) and everolimus (Zortress®): mTOR inhibitors that inhibit lymphocyte proliferation. May be used as an alternative to calcineurin inhibitors or mycophenolate in certain regimens, particularly when nephrotoxicity is a concern.
• Belatacept (Nulojix®): A selective T‑cell costimulation blocker administered intravenously; an option for kidney transplant recipients as an alternative to calcineurin inhibitor‑based regimens.

Clinical Efficacy

The pivotal phase 3 clinical trials (US Renal Transplant Mycophenolate Mofetil Study Group, European Mycophenolate Mofetil Cooperative Study Group, and Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group) demonstrated that mycophenolate mofetil, in combination with cyclosporine and corticosteroids, significantly reduced the incidence of biopsy‑proven acute rejection within the first 6 months after renal transplantation compared with azathioprine or placebo. Acute rejection rates were reduced from 40‑50% in control arms to 15‑20% in the mycophenolate mofetil 2 g/day group. Long‑term follow‑up showed improved graft survival at 3 years. In cardiac transplantation, a randomized trial of 650 patients showed that mycophenolate mofetil 3 g/day significantly reduced 1‑year mortality and the need for rejection treatment compared with azathioprine. In hepatic transplantation, mycophenolate mofetil reduced acute rejection episodes when used in combination with cyclosporine and corticosteroids. Mycophenolate mofetil is now standard of care in most solid organ transplant immunosuppressive protocols, and its use has been associated with improved long‑term graft and patient survival outcomes.

Important:

CellCept (mycophenolate mofetil) is a powerful immunosuppressive prescription medication that must be used only under the supervision of a transplant specialist or physician experienced in immunosuppressive therapy. This drug carries a boxed warning for embryo‑fetal toxicity, including severe birth defects and miscarriage. Women of childbearing potential must have a negative pregnancy test before initiating therapy, must use two reliable forms of contraception simultaneously before, during, and for 6 weeks after treatment, and must not breastfeed. Mycophenolate increases the risk of lymphoma and other malignancies, particularly skin cancers. Serious life‑threatening infections, including cytomegalovirus, BK virus‑associated nephropathy, and progressive multifocal leukoencephalopathy, may occur. Regular monitoring of blood counts, renal function, and liver function is mandatory. Do not receive live vaccines during treatment. Avoid sun exposure and use effective sun protection. Do not donate blood during or for 6 weeks after therapy. If you miss a dose, take it as soon as possible unless the next dose is due within 6 hours. Any sign of infection, unusual bruising, or bleeding must be reported immediately. Never stop taking this medication without the explicit instruction of your transplant team, as abrupt discontinuation can lead to acute graft rejection and loss of the transplanted organ. Keep out of reach of children and never share your medication with anyone else.

How to buy Generic CellCept no prescription U.S. Online Pharmacy